Development of "a full stack of host-response solutions to infectious disease testing to address outpatient and inpatient testing for acute infections and sepsis both during and outside of influenza…

Ended Definitive Contract Awarded Last action

Contract number
75A50119C00034
Awardee
Awarding agency
Obligated
$27,992,717

Award facts

Contract value 100% obligated
$27,992,717.01 Current and potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Sharing
Place of performance
Hillsborough, CA 94010, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00012 · EOI::presidential cost savings initiative (february 26, 2025)::EOI modification to transmit fpds data $0
Other Administrative Action P00011 -$1
Supplemental Agreement for work within scope P00010 · Add supplemental funding $2,352,124
Other Administrative Action P00009 · HHS clause 352.232-71 electronic submission of payment requests $0
Change Order P00008 $0
Supplemental Agreement for work within scope P00007 $0
Exercise an Option P00006 $12,183,772
Other Administrative Action P00005 $0
Other Administrative Action P00004 $0
Exercise an Option P00003 $7,458,876
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $5,997,946
Show all 13

About this award

The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract valued at approximately $28 million to Inflammatix, Inc. for the development of a comprehensive host-response diagnostic solution addressing infectious disease testing in both outpatient and inpatient settings. The contract, awarded September 25, 2019, with an ultimate completion date of May 7, 2027, supports Inflammatix's work in creating rapid point-of-care diagnostic tests that analyze immune system biomarkers to detect acute infections and sepsis across seasonal variations. The contract employs a cost-sharing pricing structure and includes no set-aside designation. Work will be performed at Inflammatix's facility in Burlingame, California.

Inflammatix specializes in molecular diagnostics leveraging machine learning and gene expression analysis to develop novel diagnostic cartridges and prognostic tools for critical clinical conditions. The company has successfully executed multiple federal contracts and grants totaling over $29 million from HHS and the National Institutes of Health for related diagnostic development initiatives, including the HOSTDX-Sepsis test and Triverity cartridge for infection severity detection. This contract aligns with the federal government's broader preparedness and response objectives by advancing diagnostic capabilities that can improve patient stratification and treatment outcomes during both routine operations and public health emergencies.

Description

Development of "a full stack of host-response solutions to infectious disease testing to address outpatient and inpatient testing for acute infections and sepsis both during and outside of influenza season"

Quick answers

Who was awarded contract 75A50119C00034?

75A50119C00034 was awarded to Inflammatix, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 25, 2019.

How much is contract 75A50119C00034 worth?

The government has obligated $27,992,717 on 75A50119C00034.

Was contract 75A50119C00034 competed?

The extent of competition for 75A50119C00034 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award